mirikizumab (LY3074828) - Eli Lilly
Mirikizumab: Primary completion of P3 LUCENT 1 trial (NCT03518086) in moderate-to-severe ulcerative colitis in Sep 2020 (Eli Lilly) - Oct 23, 2019 - Q3 2019 Results: Completion of P3 LUCENT 1 trial in moderate-to-severe ulcerative colitis in Dec 2021; Primary completion and completion of P2 SHINE 1 trial (NCT04004611) in children and teenagers with ulcerative colitis in Aug 2022 
Trial completion date • Trial primary completion date
https://investor.lilly.com/static-files/c4eae44d-aea0-4f4b-90d9-d7e6d86412af
 
Oct 23, 2019
 
 
9c37141f-3a4f-481b-9aaa-7059100eaee1.jpg